

SUPPLEMENTARY MATERIAL

Title: Patient Experiences of Bullous Pemphigoid: Symptoms and Health-Related Quality of Life Impacts

Calvin N. Ho, Lila Bahadori, Marc Yale, Naomi Bishop, Caroline Roberts, Oren Meyers, Julie Bailey and Neil J. Korman

Dr Calvin N. Ho (corresponding author)

Late-Stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, 1 Medimmune Way Gaithersburg, MD 20878, USA, Email:

calvin.ho@astrazeneca.com

Dr Lila Bahadori

Late-Stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA

Mr Marc Yale

International Pemphigus and Pemphigoid Foundation, Roseville, CA, USA

Dr Naomi Bishop

Patient, New York, NY, USA

Ms Caroline Roberts

Patient Centered Solutions, IQVIA, New York, NY, USA

Dr Oren Meyers

Patient Centered Solutions, IQVIA, New York, NY, USA

Ms Julie Bailey

Patient Centered Solutions, IQVIA, New York, NY, USA

Dr Neil J. Korman

University Hospitals Cleveland Medical Center, Cleveland, OH, USA

Supplementary Table 1. Demographic and clinical characteristics of participants in the United States

Characteristic	Total
Total number of participants in the United States, N	23
Age, years	
Mean (standard deviation)	63.2 (14.1)
Minimum – maximum	31–84
Gender, n (%)	
Female	14 (60.9)
Male	9 (39.1)
Race/ethnicity, n (%)	
White	21 (91.3)
Black or African American	1 (4.3)
Hispanic/Latino/Latina/Latinx	1 (4.3)
Work status, n (%)	
Retired	11 (47.8)
Not employed	4 (17.4)
Part time employed	4 (17.4)
Not working due to health	2 (8.7)
Full time employed	2 (8.7)
Time since symptom onset, n (%)	
≤1 year	9 (39.1)
2 years	2 (8.7)
3 years	2 (8.7)
4 years	1 (4.3)
≥5 years	3 (13.0)
Not known/not remembered	6 (26.1)
Past treatments,^a n (%)	
Corticosteroids – oral	18 (78.3)
Corticosteroids – topical	17 (73.9)
Immunosuppressants ^b	13 (56.5)
Creams/ointments	10 (43.5)
Antibiotics	12 (52.2)
Antibiotics – general	10 (43.5)
Antibiotics – dapsone ^c	2 (8.7)
Monoclonal antibodies	11 (47.8)
Other ^d	20 (86.9)

^aTreatments were reported by participants and were not confirmed through medical records.

^bImmunosuppressants such as mycophenolate, methotrexate, and azathioprine. ^cParticipants who had been previously prescribed dapsone treatment indicated this was due to medical

providers believing leprosy was a possible cause of their BP symptoms. ^dIncluded vitamins, over-the-counter medications (such as allergy medication and antihistamines), treatments unspecified by participants, and other treatments (such as triamcinolone acetonide, gabapentin, clobetasol, and intravenous therapy).

N/n, number of participants.